BCLC分期与治疗算法的价值与边界:从过去学习,以新提案改善未来
本文深度分析巴塞罗那临床肝癌(BCLC)分期与治疗算法自1999年以来对肝细胞癌(HCC)管理的标准化作用及其演变优势,指出近二十年来患者特征与治疗选择的变化限制了BCLC标准在越来越多患者中分配治疗的作用,尤其在早期以外HCC中严格依从BCLC标准在专家中心有限;提出整合临床因素、生物标志物、技术可行性与资源可及性的「多参数治疗层级」新概念,并引入「反向治疗层级」概念。
要点
- BCLC系统自1999年标准化HCC管理,提供预后评估与治疗的结构化方法。
- 近二十年患者特征与可用治疗变化,限制BCLC标准在越来越多患者中分配治疗的作用。
- 严格依从BCLC标准在专家中心有限,尤其对早期以外HCC患者。
核心结论
- BCLC系统仍是评判其他治疗框架的基准,但精准医学时代要求由多学科肿瘤委员会进行患者量身定制的治疗决策,而非按分期决定治疗分配。
- 文章提出整合临床因素、生物标志物、技术可行性与资源可及性综合评估的「多参数治疗层级」新概念。
- 考虑局部区域与系统治疗疗效增加,引入「反向治疗层级」概念,这些治疗可提高潜在治愈方法的可行性(转化途径)与有效性(系统治疗辅助途径)。
研究设计与样本
- 本文为专家意见(Expert Opinion),对BCLC分期与治疗算法进行深入分析。
主要发现
- BCLC系统自1999年以来标准化HCC管理,提供预后评估与治疗的结构化方法。
- 近二十年来患者特征与可用治疗均已变化,限制了BCLC标准在越来越多患者中分配治疗的作用。
- 随着治疗选择扩展且更有效,与分期挂钩的治疗决策算法可能导致早期以外HCC患者治疗不足和次优结局。
- 严格依从BCLC标准在专家中心有限,尤其对诊断时已超出早期HCC的患者。
临床怎么用
- 作者认为,精准医学时代要求由多学科肿瘤委员会进行患者量身定制的治疗决策,而非按分期决定治疗分配。
- 作者提出「多参数治疗层级」,整合临床因素、生物标志物、技术可行性与资源可及性的综合评估。
- 作者引入「反向治疗层级」概念,局部区域与系统治疗可提高潜在治愈方法的可行性(转化途径)与有效性(系统治疗辅助途径)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this Expert Opinion, we thoroughly analyse the Barcelona Clinic Liver Cancer (BCLC) staging and treatment algorithm for hepatocellular carcinoma (HCC) that, since 1999, has standardised HCC management, offering a structured approach for the prognostic evaluation and treatment of patients with HCC. The first part of the article presents the strengths and evolutionary improvements of the BCLC staging system. Nevertheless, both patient characteristics and available treatments have changed in the last two decades, limiting the role of the BCLC criteria for treatment allocation in a growing number of patients. As therapeutic options expand and become more effective, the stage-linked treatment decision-making algorithm may lead to undertreatment and suboptimal outcomes for patients with disease beyond early-stage HCC. Consequently, strict adherence to BCLC criteria is limited in expert centres, particularly for patients diagnosed beyond early-stage HCC. Although the BCLC system remains the benchmark against which other therapeutic frameworks must be judged, the era of precision medicine calls for patient-tailored therapeutic decision-making (by a multidisciplinary tumour board) rather than stage-dictated treatment allocation. Acknowledging this conceptual difference in clinical management, the second part of the article describes a novel "multiparametric therapeutic hierarchy", which integrates a comprehensive assessment of clinical factors, biomarkers, technical feasibility, and resource availability. Lastly, considering the increasing efficacy of locoregional and systemic treatments, the concept of "converse therapeutic hierarchy" is introduced. These treatments can increase the feasibility (conversion approach) and effectiveness (adjuvant approach of systemic therapy) of potentially curative approaches to greatly improve clinical outcomes.
引用
- Trevisani F, Vitale A, Kudo M, et al. Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal. J Hepatol. 2024. PMID: 38266658. doi:10.1016/j.jhep.2024.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。